Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Financial Officer | February 08, 2019 | February 11, 2019 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Chief Financial Officer | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 08, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.89 · Expires 2029-02-07 | Direct | 35,000 |
Reported balance
After 2019-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-08 · Grant · Acquired 35,000 · Balance 35,000 F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
Oric Pharmaceuticals, Inc.
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,828 |
Ending reported balance
After 2026-09-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-24 · Exercise / conversion · Acquired 600 · Balance 70,428 Row 2 · 2026-09-24 · Sale · Disposed 100 · Balance 70,328 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. Row 3 · 2026-09-24 · Sale · Disposed 500 · Balance 69,828 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2032-07-19 | Direct | 91,900 |
Reported balance
After 2026-09-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-24 · Exercise / conversion · Disposed 600 · Balance 91,900 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2022 Filed Feb 17, 2023 21:23 UTC Amendment | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 2,227 | $3.08 | $6,854.04 |
DisclosureSEC source: 0001209191-23-010611 · doc4a.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,285 F1 · kind: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · shares: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. F1 · price: This amendment is filed to correct the number of shares sold, and the price per share at which the shares were sold, to cover the tax withholding obligations in connection with the vesting of RSUs reported in the Form 4 filed December 16, 2022 and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 108,750 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 8 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 108,750 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F7 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 7 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F7 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option shall vest on July 20, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 86,250 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 6 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,250 Underlying: Common Stock · 86,250 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 207,500 | Not disclosed Strike: $4.36 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,500 Underlying: Common Stock · 207,500 shares Expires 2032-07-19 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F6 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on July 20, 2023, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 108,750 | Not disclosed Strike: $9.48 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,750 shares Expires 2032-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F5 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option would have vested on February 1, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option would have vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $29.83 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2031-01-31 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F4 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 86,250 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 86,250 shares Expires 2030-04-22 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F3 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on April 23, 2021, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. Read SEC document |
| July 20, 2022 Filed Jul 21, 2022 20:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Disposition to issuerStock Option (right to buy) · Derivative | 207,500 | Not disclosed Strike: $6.44 | Not disclosed |
DisclosureSEC source: 0001209191-22-042842 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 207,500 shares Expires 2029-09-10 F2 · price: On July 20, 2022, in connection with the Issuer's option exchange program, the Issuer exchanged the Reporting Person's outstanding option on a 1:1 basis with a post-exchange exercise price of $4.36 per share. F1 · derivative.exercise_date: Twenty five percent (25%) of the shares subject to the option vested on September 10, 2020, and one forty-eighth (1/48th) of the shares subject to the option vested each month thereafter. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 00:51 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | PurchaseCommon Stock | 60,000 | $5.36 | $321,624.00 |
DisclosureSEC source: 0001209191-22-021875 · doc4.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · price: Represents the weighted average share price of an aggregate total of 60,000 shares purchased in the price range of $5.25 to $5.46 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantRestricted Stock Unit · Derivative | 18,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006337 · doc4.xml · derivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,125 Underlying: Common Stock · 18,125 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. Common Stock. F3 · derivative.exercise_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. F3 · derivative.expiration_date: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:07 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 108,750 | $0.00 Strike: $9.48 | $0.00 |
DisclosureSEC source: 0001209191-22-006337 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,750 Underlying: Common Stock · 108,750 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2023, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 00:32 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $29.83 | $0.00 |
DisclosureSEC source: 0001209191-21-006964 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 1, 2022, and 1/36th of the remaining shares subject to the option shall vest each month thereafter. Read SEC document |
| April 23, 2020 Filed Apr 27, 2020 20:42 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 86,250 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-025808 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,250 Underlying: Common Stock · 86,250 shares Expires 2030-04-22 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 23, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009034 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · derivative · entry 8 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,241 Underlying: Common Stock · 37,000 shares Expires 2027-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 9, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F9 · balance_after: In addition to the remaining options to purchase 133,241 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 98,000 shares of common stock, which options vest according to their terms. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,100 | $75.81 | $83,390.01 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 7 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.44 to $76.26 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,624 | $74.33 | $492,361.92 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 6 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.00 to $74.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,298 | $73.18 | $168,158.68 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 5 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,724 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.93 to $73.28 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,820 | $72.24 | $348,212.22 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 4 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,022 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.91 to $72.90 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 18,604 | $71.33 | $1,327,060.53 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 3 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,842 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,554 | $70.34 | $249,974.14 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 2 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,446 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 03, 2018 Filed Dec 5, 2018 02:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 37,000 | $11.34 | $419,580.00 |
DisclosureSEC source: 0001209191-18-061100 · doc4.xml · nonDerivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:16 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $106.84 | $0.00 |
DisclosureSEC source: 0001209191-18-006000 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 26, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:44 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015447 · doc4.xml · derivative · entry 1 Piscitelli Dominic · CIK 0001695028 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 24, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.